CVC and GBL launch €10.7B bid to take Recordati private

CVC Capital Partners and Groupe Bruxelles Lambert have formally launched a voluntary cash tender offer to acquire all outstanding shares of Italian drugmaker Recordati for €51.29 per share, valuing the deal at about €10.7 billion and setting up a potential delisting from Euronext Milan. The bid follows CVC’s non-binding approach in March and is being made through a new vehicle, Respighi BidCo. Recordati’s controlling shareholder, Rossini, has already committed to tender its 46.82% stake, and the consortium says the offer is fully financed, with backing from co-investors including ADIA, CPP Investments, PSP, StepStone, AlpInvest, CapSol, MGG Strategic, and Andrea Recordati. (gbl.com)

Why it matters: For veterinary professionals, this is mainly a signal about capital flows and strategic pressure across European healthcare, rather than an immediate change to clinical practice. Recordati is a human pharma company, not a major animal health manufacturer, but a take-private move of this size shows investors still see room to create value through portfolio reshaping, R&D investment, and M&A. That matters because large healthcare deals can influence competition for assets, specialty distribution relationships, and the broader financing environment that also touches animal health and veterinary-adjacent businesses. (gbl.com)

What to watch: The next milestones are regulatory approvals, whether the consortium reaches the 66.67% acceptance threshold, and whether it can secure enough shares to complete a delisting later in 2026. (gbl.com)